Ken Griffin Delcath Systems, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 56,700 shares of DCTH stock, worth $678,132. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,700
Previous 11,700
384.62%
Holding current value
$678,132
Previous $97,000
427.84%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding DCTH
# of Institutions
73Shares Held
7.62MCall Options Held
198KPut Options Held
41.7K-
Aigh Capital Management LLC Baltimore, MD1.78MShares$21.3 Million6.51% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.11MShares$13.3 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA997KShares$11.9 Million1.32% of portfolio
-
Essex Investment Management CO LLC Boston, MA337KShares$4.03 Million0.57% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny312KShares$3.73 Million0.0% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $103M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...